Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Curosurf for infant respiratory distress syndrome
ACTRN12610000857000Phase 3Terminated
- Sponsor
- School of Women's and Infants' Health
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by School of Women's and Infants' Health. Primary endpoints: Need for intubation and Duration of mechanical ventilation. Started Oct 2010; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ACTRN12610000857000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000857000.